Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janice Lu

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Journal of Hematology & Oncology|August 13, 2015
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancerJanice Lu
Journal of Hematology & Oncology|October 3, 2008
Novel therapies in breast cancer: what is new from ASCO 2008David Chu, Janice Lu
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging treatments for ovarian cancerFranco Muggia, M Janice Lu
Journal of Hematology & Oncology|June 13, 2018
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancerAnishka D'Souza, Darcy Spicer, Janice Lu
Journal of Hematology & Oncology|December 25, 2024
Current and future immunotherapy for breast cancerNatalie K Heater, Surbhi Warrior, Janice Lu
Journal of Hematology & Oncology|June 5, 2013
Targeted therapy for HER2 positive breast cancerJason A Incorvati, Shilpan Shah, Ying Mu, et al.
The Lancet. Oncology|January 29, 2008
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysisShenhong Wu, John J Chen, Andrzej Kudelka, et al.
Cancers|February 10, 2024
Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer SubtypesPushpinder Kaur, Alexander Ring, Tania B Porras, et al.
British Journal of Cancer|August 29, 2021
Identification of putative actionable alterations in clinically relevant genes in breast cancerPushpinder Kaur, Tania B Porras, Anthony Colombo, et al.
Oncotargets and Therapy|December 10, 2015
Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyYunchao Wang, Tao Sun, Donggui Wan, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Journal of Hematology & Oncology|August 13, 2015
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancerJanice Lu
Journal of Hematology & Oncology|October 3, 2008
Novel therapies in breast cancer: what is new from ASCO 2008David Chu, Janice Lu
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging treatments for ovarian cancerFranco Muggia, M Janice Lu
Journal of Hematology & Oncology|June 13, 2018
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancerAnishka D'Souza, Darcy Spicer, Janice Lu
Journal of Hematology & Oncology|December 25, 2024
Current and future immunotherapy for breast cancerNatalie K Heater, Surbhi Warrior, Janice Lu
Journal of Hematology & Oncology|June 5, 2013
Targeted therapy for HER2 positive breast cancerJason A Incorvati, Shilpan Shah, Ying Mu, et al.
The Lancet. Oncology|January 29, 2008
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysisShenhong Wu, John J Chen, Andrzej Kudelka, et al.
Cancers|February 10, 2024
Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer SubtypesPushpinder Kaur, Alexander Ring, Tania B Porras, et al.
British Journal of Cancer|August 29, 2021
Identification of putative actionable alterations in clinically relevant genes in breast cancerPushpinder Kaur, Tania B Porras, Anthony Colombo, et al.
Oncotargets and Therapy|December 10, 2015
Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyYunchao Wang, Tao Sun, Donggui Wan, et al.
Pageof 4